European Journal of Cardiovascular Medicine

Aim and Background: In every region of the world, alcoholic liver disease can be attributed to alcoholism, which is one of the most prevalent risk factors. The goals of this study were to determine whether or not Kallistatin is a helpful non-invasive diagnostic for the diagnosis of alcoholic liver disease; whether or not its utility correlates with disease severity.

Methods: This case control research included a total of 75 human participants. This study was conducted at the Department of Biochemistry, Government Medical College, Sircilla, Telangana, India between June 202 to May 2023. During their visit for non-hepatic causes, controls were enlisted from the outpatient department. We chose 25 people who appeared to be in good health, had a history of abstaining completely from alcohol, and had a normal USG of the abdomen. Based on compensated and decompensated features, 50 cases were chosen and split into two groups. Serum Kallistatin concentrations were determined using a regular automated analyzer and Kallistatin levels were analyzed using an Enzyme Linked Immunosorbent Assay.

Results: Serum kallistatin levels were found to be inversely proportional to the severity of liver injury. Thirty patients with compensated aspects of alcoholic liver disease make up Group 1, and thirty patients with decompensated features of alcoholic liver disease make up Group 2.

Conclusion: Serum kallistatin can be used to detect early liver damage caused by alcohol intake. Serum kallistatin levels may be an important and protective factor in the prevention of alcoholic liver damage. This study paves the way for therapeutic intervention to begin earlier based on blood kallistatin levels.